
## Maria Vincenza Mastrolia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7077668/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A spectrum of inflammation and demyelination in acute disseminated encephalomyelitis (ADEM) of children. Autoimmunity Reviews, 2015, 14, 923-929.	5.8	59
2	Characteristics and outcome of influenza-associated encephalopathy/encephalitis among children in a tertiary pediatric hospital in Italy, 2017–2019. BMC Infectious Diseases, 2019, 19, 1012.	2.9	37
3	Vaccine administration in children with chronic kidney disease. Vaccine, 2014, 32, 6601-6606.	3.8	28
4	Use of tigecycline in pediatric clinical practice. Expert Review of Anti-Infective Therapy, 2017, 15, 605-612.	4.4	21
5	Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): clues and pitfalls in the pediatric background. Immunologic Research, 2014, 60, 366-375.	2.9	20
6	Metapneumovirus Infections and Respiratory Complications. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 512-521.	2.1	20
7	The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2095957.	2.7	17
8	Ocular involvement in monogenic autoinflammatory disease. Autoimmunity Reviews, 2021, 20, 102944.	5.8	17
9	Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment. Critical Care, 2021, 25, 131.	5.8	12
10	Utility of tuberculin skin test and IGRA for tuberculosis screening in internationally adopted children: Retrospective analysis from a single center in Florence, Italy. Travel Medicine and Infectious Disease, 2019, 28, 64-67.	3.0	10
11	Septic arthritis in children in resource limited and non-resource limited countries: an update on diagnosis and treatment. Expert Review of Anti-Infective Therapy, 2016, 14, 1087-1096.	4.4	9
12	The Role of Anti-IL-1 Treatment in MIS-C Patients. Expert Opinion on Biological Therapy, 2022, 22, 1-5.	3.1	9
13	A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine. Clinical and Experimental Rheumatology, 2022, 40, 457-470.	0.8	9
14	The Development of Extra-Articular Manifestations in Children With Enthesitis-Related Arthritis: Natural Course or Different Disease Entity?. Frontiers in Medicine, 2021, 8, 667305.	2.6	7
15	Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults. Expert Review of Vaccines, 2014, 13, 1059-1066.	4.4	6
16	Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110025.	2.7	4
17	Correspondence on â€~Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort'. Annals of the Rheumatic Diseases, 2022, 81, e218-e218.	0.9	3
18	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis. Scientific Reports, 2021, 11, 16393.	3.3	3

#	Article	IF	CITATIONS
19	Diagnostic challenge of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome in pediatric age: A monocentric case series. Modern Rheumatology, 2021, 31, 1228-1231.	1.8	2
20	Mycophenolate mofetil-induced hypogammaglobulinemia and infectious disease susceptibility in pediatric patients with chronic rheumatic disorders: a monocentric retrospective study. European Journal of Pediatrics, 2022, 181, 3439-3448.	2.7	2
21	Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long. Clinical and Experimental Rheumatology, 2021, 39, 697-699.	0.8	1
22	Non-Infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era. Current Treatment Options in Rheumatology, 2020, 6, 228-244.	1.4	0
23	Non-infectious Chronic Uveitis in Childhood: Assessment and Treatment in the Biological Era. Current Treatment Options in Rheumatology, 2021, 7, 82-97.	1.4	0
24	Successful treatment of adalimumab in a child with Vogt-Koyanagi-Harada: which is the best available systemic treatment?. Clinical and Experimental Rheumatology, 2021, 39, 1453-1454.	0.8	0
25	The decrease of Kawasaki syndrome during the second COVID-19 wave: a potential, unexpected effect of social distancing. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
26	A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: an evidence gap in precision medicine Clinical and Experimental Rheumatology, 2021, , .	0.8	0